Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK500691PMID: 29999750
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 171099-57-3
Drug Levels and Effects
Summary of Use during Lactation
Because oritavancin is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Monitor the infant for possible effects on the gastrointestinal tract, such as diarrhea, vomiting, and candidiasis (e.g., thrush, diaper rash). However, because there is no published experience with oritavancin during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
Clindamycin, Daptomycin, Doxycycline, Trimethoprim-Sulfamethoxazole, Vancomycin
Substance Identification
Substance Name
Oritavancin
CAS Registry Number
171099-57-3
Drug Class
Breast Feeding
Lactation
Anti-Infective Agents
Anti-Bacterial Agents
Glycopeptides
Lipoglycopeptides
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.